$1.20
-0.03-2.50%
At close: Jul 18, 5:10 PM EDT
$1.17
-0.03-2.50%
After Hours: Jul 18, 5:10 PM EDT
15 minutes delayed
Comments
Loading...
DarioHealth
DRIONASDAQ
DarioHealth (NASDAQ:DRIO) Stock, Analyst Ratings, Price Targets, Forecasts
DarioHealth Corp has a consensus price target of $9.02 based on the ratings of 5 analysts. The high is $15 issued by Aegis Capital on August 18, 2022. The low is $4 issued by Stifel on April 1, 2024. The 3 most-recent analyst ratings were released by Stifel, Alliance Global Partners, and Stifel on April 1, 2024, August 11, 2023, and July 25, 2023, respectively. With an average price target of $4.7 between Stifel, Alliance Global Partners, and Stifel, there's an implied 301.71% upside for DarioHealth Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Alliance Global Partners
Craig-Hallum
Aegis Capital
Cowen & Co.
1calculated from analyst ratings
Analyst Ratings for DarioHealth
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/01/2024 | Buy Now | 241.88% | Stifel | David Grossman | → $4 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 250.43% | Alliance Global Partners | Ben Haynor | $5.45 → $4.1 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | 412.82% | Stifel | David Grossman | $9 → $6 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 583.76% | Craig-Hallum | Alexander Nowak | $14 → $8 | Maintains | Buy | Get Alert |
| 11/16/2022 | Buy Now | 541.03% | Alliance Global Partners | Ben Haynor | $9.15 → $7.5 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | 1182.05% | Aegis Capital | Nathan Weinstein | $20 → $15 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | 1096.58% | Cowen & Co. | Charles Rhyee | $18 → $14 | Maintains | Outperform | Get Alert |
| 05/16/2022 | Buy Now | 1609.4% | Aegis Capital | Nathan Weinstein | $23 → $20 | Maintains | Buy | Get Alert |
| 05/16/2022 | Buy Now | 1438.46% | Cowen & Co. | Charles Rhyee | $14 → $18 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | — | Alliance Global Partners | Ben Haynor | — | Upgrade | Neutral → Buy | Get Alert |
| 01/26/2022 | Buy Now | 2036.75% | Aegis Capital | Nathan Weinstein | $28 → $25 | Maintains | Buy | Get Alert |
| 08/19/2021 | Buy Now | 2293.16% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for DarioHealth (DRIO) stock?
The latest price target for DarioHealth (NASDAQ:DRIO) was reported by Stifel on April 1, 2024. The analyst firm set a price target for $4.00 expecting DRIO to rise to within 12 months (a possible 241.88% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for DarioHealth (DRIO)?
The latest analyst rating for DarioHealth (NASDAQ:DRIO) was provided by Stifel, and DarioHealth maintained their buy rating.
When was the last upgrade for DarioHealth (DRIO)?
The last upgrade for DarioHealth Corp happened on May 13, 2022 when Alliance Global Partners raised their price target to N/A. Alliance Global Partners previously had a neutral for DarioHealth Corp.
When was the last downgrade for DarioHealth (DRIO)?
There is no last downgrade for DarioHealth.
When is the next analyst rating going to be posted or updated for DarioHealth (DRIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DarioHealth, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DarioHealth was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
Is the Analyst Rating DarioHealth (DRIO) correct?
While ratings are subjective and will change, the latest DarioHealth (DRIO) rating was a maintained with a price target of $0.00 to $4.00. The current price DarioHealth (DRIO) is trading at is $1.17, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.